Evidence map›Paper›PMID 31086173›Full record

ArticleOncogenesis2019

Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB.

Faranak Mahjour, Vrinda Dambal, Neha Shrestha, Varun Singh, Vikki Noonan, Alpdogan Kantarci, Philip C Trackman

Open access · goldAbstract read
In one paragraph

Article in Oncogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. LOXL2 in Cancer: A Two-Decade Perspective.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Article
  12. Crystal structures of di-μ-chlorido-bis-({(Acta crystallographica. Section E, Crystallographic communications · 2023
    Article
  13. Article
  14. Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Mass Spectrometry-Based Disulfide Mapping of Lysyl Oxidase-like 2.International journal of molecular sciences · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Faranak MahjourBoston University Henry M. Goldman School of Dental Medicine, Department of Molecular and Cell Biology, Boston, MA, 02118, USA.
Vrinda DambalBoston University Henry M. Goldman School of Dental Medicine, Department of Molecular and Cell Biology, Boston, MA, 02118, USA.
Neha ShresthaBoston University Henry M. Goldman School of Dental Medicine, Department of Molecular and Cell Biology, Boston, MA, 02118, USA.
Varun SinghBoston University Henry M. Goldman School of Dental Medicine, Department of Molecular and Cell Biology, Boston, MA, 02118, USA.
Vikki NoonanBoston University Henry M. Goldman School of Dental Medicine, Division of Oral & Maxillofacial Pathology, Boston, MA 02118, USA.
Alpdogan KantarciForsyth Institute, Cambridge, MA, 02142, USA.
Philip C TrackmanBoston University Henry M. Goldman School of Dental Medicine, Department of Molecular and Cell Biology, Boston, MA, 02118, USA. trackman@bu.edu.ORCID http://orcid.org/0000-0001-5064-614X
Boston University · US

Funding

Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral CancerR21DE023973 · NIDCR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TRACKMAN, PHILIP C · 2014 to 2015
$450k
In Vivo Imaging Analysis System - Xenogen IVIS SpectrumS10RR024523 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GERSTENFELD, LOUIS CHARLES · 2008 to 2008
$350k
NCRR NIH HHS S10 RR024523NIDCR NIH HHS R21 DE023973U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) DE023973
6 · The paper itself

Abstract

Extracellular lysyl oxidases (LOX and LOXL1-LOXL4) are critical for collagen biosynthesis. LOXL2 is a marker of poor survival in oral squamous cell cancer. We investigated mechanisms by which tumor cell secreted LOXL2 targets proximal mesenchymal cells to enhance tumor growth and metastasis. This study identified the first molecular mechanism for LOXL2 in the promotion of cancer via its enzymatic modification of a non-collagenous substrate in the context of paracrine signaling between tumor cells and resident fibroblasts. The role and mechanism of active LOXL2 in promoting oral cancer was evaluated and employed a novel LOXL2 small molecule inhibitor, PSX-S1C, administered to immunodeficient, and syngeneic immunocompetent orthotopic oral cancer mouse models. Tumor growth, histopathology, and metastases were monitored. In vitro mechanistic studies with conditioned tumor cell medium treatment of normal human oral fibroblasts were carried out in the presence and absence of the LOXL2 inhibitor to identify signaling mechanisms promoted by LOXL2 activity. Inhibition of LOXL2 attenuated cancer growth and lymph node metastases in the orthotopic tongue mouse models. Immunohistochemistry data indicated that LOXL2 expression in and around tumors was decreased in mice treated with the inhibitor. Inhibition of LOXL2 activity by administration of PXS-S1C to mice reduced tumor cell proliferation, accompanied by changes in morphology and in the expression of epithelial to mesenchymal transition markers. In vitro studies identified PDGFRβ as a direct substrate for LOXL2, and indicated that LOXL2 and PDGF-AB together secreted by tumor cells optimally activated PDGFRβ in fibroblasts to promote proliferation and the tendency toward fibrosis via ERK activation, but not AKT. Optimal fibroblast proliferation in vitro required LOXL2 activity, while tumor cell proliferation did not. Thus, tumor cell-derived LOXL2 in the microenvironment directly targets neighboring resident cells to promote a permissive local niche, in addition to its known role in collagen maturation.

Identifiers

PMID31086173
PMCPMC6513832
OpenAlexW2946752144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.